GYNECOLOGIC CANCERS

Matthew A. Powell, MD, reviews key takeaways from the Study-309/KEYNOTE-775 trial investigating lenvatinib plus pembrolizumab for the treatment for endometrial cancer.

Dr Matthew A. Powell details the rationale for using single-agent immunotherapy treatments for patients with advanced or recurrent endometrial cancer with reference to data updates from several key clinical trials.

Matthew A. Powell, MD, shares an overview of the systemic treatment options for patients with relapsed or metastatic endometrial cancer and the factors he considers when selecting an appropriate frontline therapy.

Dr Matthew A. Powell reviews the study design and key endpoints of the RUBY trial in dMMR endometrial cancer and explains the potential clinical implications of the data.

Medical expert provides an overview of the recommended biomarker testing for endometrial cancer and the frontline treatment options available for patients with dMMR/MSI-high endometrial cancer.

The first randomized study of immune checkpoint inhibitor therapy in platinum-sensitive ovarian cancer has missed its key end point.

Ruchi Garg, MD, discusses the impact of targeted therapies studies in patients with early and recurrent endometrial cancer.

John Diaz, MD, discusses some known biomarkers in ovarian cancer and where he hopes to see more research in the future.

Topline results reported from the UPLIFT trial showed it did not meet its primary end point of objective response rate in the NaPi2b-positive population with ovarian cancer.

Investigators are evaluating the efficacy and safety of selinexor vs placebo when used as a maintenance therapy for patients with p53 wild-type advanced or recurrent endometrial cancer.

Bradley J. Monk, MD, FACS, FACOG, discusses the rationale behind the KEYNOTE-826 study.

Enrollment in the confirmatory phase 3 RAMP 301 study of avutometinib combined with defactinib in low-grade serous ovarian cancer is anticipated to begin in the second half of this year.

In an interview with Targeted Oncology, Bradley J. Monk, MD, FACCOG, FACS, highlighted final results from the phase 3 KEYNOTE-826 trial of pembrolizumab plus chemotherapy vs chemotherapy plus placebo, with or without bevacizumab in persistent, recurrent, or metastatic cervical cancer.

Anna Jo Bodurtha Smith, MD, MPH, MSc, discusses her research on issues facing patients who need care for gynecologic cancers who have private insurance in the United States.

The combination of avutometinib with defactinib elicited high activity in patients with recurrent low-grade serous ovarian cancer, according to data from RAMP 201.

John P. Diaz, MD, discusses how meetings on gynecologic oncology provide advantages for everyday physicians to keep track of the latest updates on the treatment landscape.

Adjuvant chemotherapy did not lead to survival improvements vs standard chemoradiotherapy alone in patients with locally advanced cervical cancer and resulted in more severe adverse events, according to OUTBACK trial data.

Additional findings from KEYNOTE-826 reveal no negative health-related quality-of-life impact when using pembrolizumab plus chemotherapy with or without bevacizumab.

Treatment with ceralasertib with and without olaparib showed promising signals of clinical activity in multiple rare gynecologic cancers, according to findings presented at the European Society for Medical Oncology Gynaecologic Cancers Congress 2023.

Anna Jo Bodurtha Smith, MD, MPH, MSc, discusses why the number of patients with gynecologic cancer that never see a gynecologic oncologist is so high.

Significant rates of homologous recombination deficiency somatic gene mutations were found in patients with uterine serous cancer, resulting in possible implications for future testing and treatment for the patient population, according to the results of a research study.

John P. Diaz, MD, explains the importance of the topics to be discusses at the Miami Cancer Institute Women’s Cancer Symposium on April 21, 2023.

John P. Diaz, MD, provides an overview of the topics to be discusses during the Miami Cancer Institute Women’s Cancer Symposium on April 21, 2023.

At the Society of Gynecologic Oncology 2023 Annual Meeting, data showed that with a median follow-up of 25.8 months, the proportion of patients on Arm A of the NRG-GY017 trial of patients with cervical cancer with 2-year disease-free survival rate was 79% vs 59% in Arm B.

Anna Jo Bodurtha Smith, MD, discusses background on her research regarding insurance-mediated disparities in gynecologic oncology.